Kezar Life Sciences, Inc. (KZR)
7.36
-0.02
(-0.27%)
USD |
NASDAQ |
May 07, 10:29
Kezar Life Sciences Cash from Investing (Quarterly) : 51.61M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Apellis Pharmaceuticals, Inc. | -0.108M |
| ACADIA Pharmaceuticals, Inc. | -55.87M |
| Alnylam Pharmaceuticals, Inc. | -25.54M |
| Savara, Inc. | -93.56M |
| BioMarin Pharmaceutical, Inc. | 725.53M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -11.96M |
| Cash from Financing (Quarterly) | -6.707M |
| Free Cash Flow | -51.78M |
| Free Cash Flow Per Share (Quarterly) | -1.633 |
| Free Cash Flow to Equity (Quarterly) | -4.376M |
| Free Cash Flow to Firm (Quarterly) | -11.96M |
| Free Cash Flow Yield | -96.16% |